Mauricette Michallet

Laboratoire de Biologie et Modélisation de la Cellule — France

Medicine · Health Sciences

74h-index22.7kcitations632works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hematopoietic Stem Cell Transplantation(283), Acute Myeloid Leukemia Research(246), Chronic Myeloid Leukemia Treatments(171), Chronic Lymphocytic Leukemia Research(147), Acute Lymphoblastic Leukemia research(142)

Publications632 total

Impact on overall and progression-free survivals of iron chelation given 6 months after allogeneic hematopoietic stem cell transplantation for Acute Myeloid Leukemia and myelodysplastic syndrom
Blood·2025Open Access
Secondary-type acute myeloid leukemia is associated with a higher risk of invasive fungal infection during intensive induction therapy. a correlative study on the ALFA 0702 trial.
Blood·2025Open Access
Predictive factors for successful treatment-free remission in patients with chronic myeloid leukemia: A pooled analysis
Blood·2025
Azacytidine and Venetoclax As a Salvage Therapy in Measurable Residual Disease (MRD) Relapse Post Intensive Chemotherapy or Allogenic Stem Cell Transplantation in Acute Myeloid Leukemia Patients : A Multicentric Study from French Auraml Group
Blood·2024· 2 cited
Infectious Complications Among Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia: A Multicentric Real-Life Analysis of the French Auraml Group
Blood·2024· 1 citedOpen Access
Allogeneic Hematopoietic Cell Transplantation in Newly Diagnosed and Relapse/Refractory AML Patients Post Venetoclax-Azacitidine Treatment: A Multicenter Real-Life Analysis By the French Auraml Group
Blood·2024
Pharmacokinetic Consideration of Venetoclax in Acute Myeloid Leukemia Patients: A Potential Candidate for TDM? A Short Communication
Therapeutic Drug Monitoring·2023· 9 cited
Real World Use of Azacitidine and Venetoclax in Acute Myeloid Leukemia in Frontline and Relapse/Refractory Settings: A Multicentric Study from French Auraml Group
Blood·2023· 10 cited
MM-074 How can Different Therapeutic Strategies and Financial Resources Impact Outcomes After Autologous Stem Cell Transplantation in Myeloma? Study in France and Algeria
Clinical Lymphoma Myeloma & Leukemia·2023
POSTER: MM-074 How can Different Therapeutic Strategies and Financial Resources Impact Outcomes After Autologous Stem Cell Transplantation in Myeloma? Study in France and Algeria
Clinical Lymphoma Myeloma & Leukemia·2023
Clinical outcome of therapy‐related acute myeloid leukemia patients. Real‐life experience in a University Hospital and a Cancer Center in France
Cancer Medicine·2023· 5 citedOpen Access
Outcomes of graft failure after umbilical cord blood transplantation in acute leukemia: a study from Eurocord and the Acute Leukemia Working Party of the EBMT
Bone Marrow Transplantation·2023· 2 citedOpen Access
Therapy-Related Acute Myeloid Leukemia (t-AML) and the Advantage of Intensive Chemotherapy: Real-Life Analysis from Two Regional French Centers
Blood·2021
Real Life Study on Allogeneic Hematopoietic Cell Transplantation Practice According to International Guidelines and Its Impact on Survival in Acute Myeloid Leukemia French Population
Blood·2021
Improved Outcome in Young Children Compared to Adolescents and Adults After Allogeneic Hematopoietic Stem Cell Transplant for Acute Myeloid Leukemia: a Retrospective Study From Francophone Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC) (SFGM-TC)
Research Square (Research Square)·2021· 1 citedOpen Access
Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients
Nature Communications·2021· 90 citedOpen Access
Patterns of Sequelae in Women with a History of Localized Breast Cancer: Results from the French VICAN Survey
Cancers·2021· 18 citedOpen Access
Characteristics and Outcomes of Therapy-Related Acute Myeloid Leukemia: Results of Retrospective Analysis of 116 Adult Patients
Blood·2020
Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic‐phase CML in clinical practice: 3‐year European SIMPLICITY data
European Journal Of Haematology·2020· 24 citedOpen Access
A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia
Blood·2020· 50 citedOpen Access
page 1 of 32Next →

Frequent Co-authors

Michel Attal(15), Didier Blaise(14), Mohamad Mohty(12), Ibrahim Yakoub‐Agha(9), Nöel Milpied(9), Gérald Marit(8), Philippe Moreau(8), Jean‐Luc Harousseau(8), Norbert Ifrah(8), Gèrard Socié(8), Denis Caillot(6), Thierry Façon(6), Cyrille Hulin(6), Claire Mathiot(6), Hervé Avet‐Loiseau(6), Éliane Gluckman(6), Laurent Garderet(5), Tamás Masszi(5), Arnon Nagler(5), Peter Dreger(5)